Abstract

Study Design
Randomized controlled study
Purpose
To compare outcomes of low dose vs standard half-adult dose intravitreal ranibizumab (IVR) in eyes with aggressive retinopathy of prematurity (AROP)
Methods
30 eyes of 15 preterm babies with bilateral symmetrical AROP were randomized to receive IVR 0.12 mg (intervention group) in 1 eye and 0.25 mg (control group) in other eye. Additional interventions were reserved for eyes with progression or reactivation. Primary outcome was to assess disease regression at 12 weeks.
Results
All eyes had good initial regression. Total area of retinal vasculature growth was 112.24 +/- 36.2 mm2 in intervention group and 115.74 +/- 39.69 mm2 in control group (p value<0.05). No significant difference of the area of retinal vascularization was noted between both groups (p value=0.48). 7 eyes (58.3%) in each group had reactivation, needing rescue laser.
Conclusion
Lower dose of IVR has similar outcomes compared to half-adult dose of IVR for treatment of AROP